Table 7.
Available sets of MHC class I-restricted neoantigens validated to elicit a CD8+ T cell response.
| Author and Year | Tumor Type | Tested Neoantigens: Immunogenic Neoantigens | Available Sequencing Data | Mutations Tested | Prioritization Method | Validation Method |
|---|---|---|---|---|---|---|
| Robbins et al., 2013 (131) | Melanoma | 227:10 | WES | SNVs and small indels | NetMHCpan2.4 | ELISPOT |
| Wick et al., 2014 (132) | Ovarian cancer | 114:1 | WES | SNVs | NetMHCpan2.4 | ELISPOT |
| Rajasagi et al., 2014 (133) | Chronic lymphocytic leukemia | 48:3 | WES | SNVs | NetMHCpan2.4 | ELISPOT |
| Cohen et al., 2015 (134) | Melanoma | 357:9 | WES, RNAseq | SNVs | Expression >1 FPKM and MHC binding by IEDB | ELISA |
| Carreno et al., 2015 (5) | Melanoma | 21:11 | WES, RNAseq | SNVs | NetMHC2.4 | ELISA |
| McGranahan et al., 2016 (135) | Lung cancer | 355:2 | WES | SNVs | NetMHCpan2.8 | Multimers |
| Strønen et al., 2016 (136) | Melanoma | 57:11 | WES, RNAseq | SNVs | Expression >0 FPKM and NetMHC3.2, NetMHCpan2.0 | Multimers |
| Bentzen et al., 2016 (137) | Lung cancer | 702:9 | WES | SNVs | NetMHCpan2.8 | Multimers |
| Gros et al., 2016 (138) | Melanoma | 27:6 | WES, RNAseq | SNVs | VAF>10%, mutation in DNA and RNA | ELISPOT |
| Ott et al., 2017 (6) | Melanoma | 165:18 | WES, RNAseq | SNVs and small indels | NetMHCpan2.4 and oncogene mutations | ELISPOT |
| Wells et al., 2020 (22) | Melanoma and Lung cancer | 347:27 (available) | WES, RNAseq | SNVs and small indels | Consensus from 25 groups | Multimers |
Datasets were only included if they included a minimum of ten neoantigens.